Home » Topics » BioWorld Science

BioWorld Science
RSS

CRISPRa-mediated SEC23A activation rescues SEC23B-deficient CDAII in vivo

Dec. 3, 2021

Novel selective c-Abl inhibitor prevents neurodegeneration in models of Parkinson's

Dec. 3, 2021

BCL10/MALT1 axis found to be involved in psoriasis

Dec. 3, 2021

Orion completes OB-004 lead optimization

Dec. 3, 2021

GAT-564, a novel CB1R allosteric modulator with efficacy in murine model of glaucoma

Dec. 3, 2021

J2H Biotech synthesizes new compounds for liver cancer

Dec. 3, 2021

Bristol Myers Squibb synthesizes new galectin-3 inhibitors

Dec. 3, 2021

PMV Pharmaceuticals identifies new TP53 mutant stabilizers

Dec. 3, 2021

Merck & Co. divulges coagulation factor XIa inhibitors

Dec. 3, 2021

Accutar Biotechnology patents EGFR and/or HER2 inhibitors

Dec. 3, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 1, 2026.
TROP2 ADCs progress into first-line for lung, breast cancers
BioWorld
Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
New evidence links autoimmunity to long COVID symptoms
BioWorld
Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections
BioWorld
GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...